Headlines about Core Laboratories (NYSE:CLB) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Core Laboratories earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news articles about the oil and gas company an impact score of 45.7957355544418 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s scoring:
- Financial Survey: Core Laboratories (CLB) and Cameron International (CAM) (americanbankingnews.com)
- Shares Seesawing 1.97% on Volume: Core Laboratories NV (CLB) – Clawson News (clawsonnews.com)
- UPDATE: ABN Amro Downgrades Core Laboratories (CLB) to Hold – StreetInsider.com (streetinsider.com)
- Is Core Laboratories NV (CLB) a Buy? – Motley Fool (fool.com)
- Is Core Laboratories N.V. (CLB) a Buy? (finance.yahoo.com)
Core Laboratories (CLB) traded up $0.11 on Friday, reaching $119.10. 318,300 shares of the company were exchanged, compared to its average volume of 576,613. The firm has a market capitalization of $5,260.00, a price-to-earnings ratio of 68.84 and a beta of 1.56. Core Laboratories has a 52-week low of $86.55 and a 52-week high of $124.99. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 1.53.
Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.04. The firm had revenue of $166.20 million for the quarter, compared to analyst estimates of $160.94 million. Core Laboratories had a net margin of 12.06% and a return on equity of 52.89%. Core Laboratories’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.38 earnings per share. equities analysts anticipate that Core Laboratories will post 1.99 EPS for the current year.
Several brokerages have recently issued reports on CLB. Deutsche Bank lowered shares of Core Laboratories from a “buy” rating to a “hold” rating and dropped their target price for the company from $116.30 to $109.00 in a research report on Thursday. Zacks Investment Research lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. ABN Amro lowered shares of Core Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Cowen set a $100.00 target price on shares of Core Laboratories and gave the company a “hold” rating in a research report on Friday, October 6th. Finally, Piper Jaffray Companies set a $97.00 target price on shares of Core Laboratories and gave the company a “hold” rating in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company. Core Laboratories has a consensus rating of “Hold” and an average price target of $110.20.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.